{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:42:38Z","timestamp":1790480558092,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41440-022-01036-6","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T01:02:49Z","timestamp":1665709369000},"page":"19-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification"],"prefix":"10.1038","volume":"46","author":[{"given":"Rie","family":"Jo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Murai-Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mitsuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"1036_CR1","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1210\/me.2005-0089","volume":"19","author":"L Pascual-Le Tallec","year":"2005","unstructured":"Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol. 2005;19:2211\u201321.","journal-title":"Mol Endocrinol"},{"key":"1036_CR2","doi-asserted-by":"publisher","first-page":"e012","DOI":"10.1621\/nrs.05012","volume":"5","author":"S Viengchareun","year":"2007","unstructured":"Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012.","journal-title":"Nucl Recept Signal"},{"key":"1036_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1036_CR4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"1036_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"1036_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925\u201330.","journal-title":"Am J Hypertens"},{"key":"1036_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"1036_CR8","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"1036_CR9","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","volume":"29","author":"SE Nielsen","year":"2012","unstructured":"Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012;29:e184\u2013190.","journal-title":"Diabet Med"},{"key":"1036_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536\u201342.","journal-title":"Kidney Int"},{"key":"1036_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"1036_CR12","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN). Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1036_CR13","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"1036_CR14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1074\/jbc.M607741200","volume":"282","author":"K Yokota","year":"2007","unstructured":"Yokota K, Shibata H, Kurihara I, Kobayashi S, Suda N, Murai-Takeda A, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007;282:1998\u20132010.","journal-title":"J Biol Chem"},{"key":"1036_CR15","doi-asserted-by":"publisher","first-page":"8084","DOI":"10.1074\/jbc.M109.053371","volume":"285","author":"A Murai-Takeda","year":"2010","unstructured":"Murai-Takeda A, Shibata H, Kurihara I, Kobayashi S, Yokota K, Suda N, et al. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J Biol Chem. 2010;285:8084\u201393.","journal-title":"J Biol Chem"},{"key":"1036_CR16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1536\/ihj.16-649","volume":"58","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shibata H, Kurihara I, Yokota K, Mitsuishi Y, Ohashi K, et al. High glucose stimulates mineralocorticoid receptor transcriptional activity through the protein kinase C \u03b2 signaling. Int Heart J. 2017;58:794\u2013802.","journal-title":"Int Heart J"},{"key":"1036_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mce.2018.01.007","volume":"473","author":"Y Mitsuishi","year":"2018","unstructured":"Mitsuishi Y, Shibata H, Kurihara I, Kobayashi S, Yokota K, Murai-Takeda A, et al. Epidermal growth factor receptor\/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization. Mol Cell Endocrinol. 2018;473:89\u201399.","journal-title":"Mol Cell Endocrinol"},{"key":"1036_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/nature05815","volume":"446","author":"GW Hart","year":"2007","unstructured":"Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446:1017\u201322.","journal-title":"Nature."},{"key":"1036_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1146\/annurev-biochem-060608-102511","volume":"80","author":"GW Hart","year":"2011","unstructured":"Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80:825\u201358.","journal-title":"Annu Rev Biochem"},{"key":"1036_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.diabet.2010.09.001","volume":"36","author":"T Issad","year":"2010","unstructured":"Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab. 2010;36:423\u201335.","journal-title":"Diabetes Metab"},{"key":"1036_CR21","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1073\/pnas.072072399","volume":"99","author":"K Vosseller","year":"2002","unstructured":"Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 2002;99:5313\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1036_CR22","doi-asserted-by":"publisher","first-page":"10022","DOI":"10.1074\/jbc.M207787200","volume":"278","author":"GJ Parker","year":"2003","unstructured":"Parker GJ, Lund KC, Taylor RP, McClain DA. Insulin resistance of glycogen synthase mediated by o-linked N-acetylglucosamine. J Biol Chem. 2003;278:10022\u20137.","journal-title":"J Biol Chem"},{"key":"1036_CR23","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1074\/jbc.272.4.2421","volume":"272","author":"MS Jiang","year":"1997","unstructured":"Jiang MS, Hart GW. A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem. 1997;272:2421\u20138.","journal-title":"J Biol Chem"},{"key":"1036_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2337\/diabetes.51.4.1146","volume":"51","author":"LR James","year":"2002","unstructured":"James LR, Tang D, Ingram A, Ly H, Thai K, Cai L, et al. Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes. 2002;51:1146\u201356.","journal-title":"Diabetes."},{"key":"1036_CR25","doi-asserted-by":"publisher","first-page":"16283","DOI":"10.1074\/jbc.M802240200","volume":"283","author":"MP Housley","year":"2008","unstructured":"Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, et al. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem. 2008;283:16283\u201392.","journal-title":"J Biol Chem"},{"key":"1036_CR26","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1074\/jbc.M109.082685","volume":"285","author":"EH Anthonisen","year":"2010","unstructured":"Anthonisen EH, Berven L, Holm S, Nygard M, Nebb HI, Gronning-Wang LM. Nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose. J Biol Chem. 2010;285:1607\u201315.","journal-title":"J Biol Chem"},{"key":"1036_CR27","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1074\/jbc.M411820200","volume":"280","author":"I Kurihara","year":"2005","unstructured":"Kurihara I, Shibata H, Kobayashi S, Suda N, Ikeda Y, Yokota K, et al. Ubc9 and protein inhibitor of activated STAT 1 activate chicken ovalbumin upstream promoter-transcription factor I-mediated human CYP11B2 gene transcription. J Biol Chem. 2005;280:6721\u201330.","journal-title":"J Biol Chem"},{"key":"1036_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1081\/ERC-200043789","volume":"30","author":"S Kobayashi","year":"2004","unstructured":"Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, Kurihara I, et al. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr Res. 2004;30:617\u201321.","journal-title":"Endocr Res"},{"key":"1036_CR29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/nar\/11.5.1475","volume":"11","author":"JD Dignam","year":"1983","unstructured":"Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475\u201389.","journal-title":"Nucleic Acids Res"},{"key":"1036_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41440-020-00562-5","volume":"44","author":"K Yokota","year":"2021","unstructured":"Yokota K, Shibata H, Kurihara I, Kobayashi S, Murai-Takeda A, Itoh H. CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor. Hypertens Res. 2021;44:407\u201316.","journal-title":"Hypertens Res"},{"key":"1036_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156\u20139.","journal-title":"Anal Biochem"},{"key":"1036_CR32","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1210\/mend.15.9.0689","volume":"15","author":"MC Zennaro","year":"2001","unstructured":"Zennaro MC, Souque A, Viengchareun S, Poisson E, Lombes M. A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action. Mol Endocrinol. 2001;15:1586\u201398.","journal-title":"Mol Endocrinol"},{"key":"1036_CR33","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1074\/jbc.273.6.3611","volume":"273","author":"RS Haltiwanger","year":"1998","unstructured":"Haltiwanger RS, Grove K, Philipsberg GA. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. J Biol Chem. 1998;273:3611\u20137.","journal-title":"J Biol Chem"},{"key":"1036_CR34","doi-asserted-by":"publisher","first-page":"F1462","DOI":"10.1152\/ajprenal.00285.2010","volume":"299","author":"N Faresse","year":"2010","unstructured":"Faresse N, Ruffieux-Daidie D, Salamin M, Gomez-Sanchez CE, Staub O. Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP. Am J Physiol Ren Physiol. 2010;299:F1462\u20131472.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"Pt 1","key":"1036_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1042\/bj3500109","volume":"350","author":"I Han","year":"2000","unstructured":"Han I, Oh ES, Kudlow JE. Responsiveness of the state of O-linked N-acetylglucosamine modification of nuclear pore protein p62 to the extracellular glucose concentration. Biochem J. 2000;350(Pt 1):109\u201314.","journal-title":"Biochem J"},{"key":"1036_CR36","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1210\/mend.14.6.0467","volume":"14","author":"H Fuse","year":"2000","unstructured":"Fuse H, Kitagawa H, Kato S. Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol Endocrinol. 2000;14:889\u201399.","journal-title":"Mol Endocrinol"},{"key":"1036_CR37","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1210\/me.2003-0299","volume":"17","author":"L Pascual-Le Tallec","year":"2003","unstructured":"Pascual-Le Tallec L, Kirsh O, Lecomte MC, Viengchareun S, Zennaro MC, Dejean A, et al. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol. 2003;17:2529\u201342.","journal-title":"Mol Endocrinol"},{"key":"1036_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0092-8674(00)81294-5","volume":"84","author":"H Chen","year":"1996","unstructured":"Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db\/db mice. Cell. 1996;84:491\u20135.","journal-title":"Cell."},{"key":"1036_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1126\/science.153.3740.1127","volume":"153","author":"KP Hummel","year":"1966","unstructured":"Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153:1127\u20138.","journal-title":"Science."},{"key":"1036_CR40","first-page":"3220","volume":"39","author":"AA Ovejera","year":"1979","unstructured":"Ovejera AA, Houchens DP, Catane R, Sheridan MA, Muggia FM.Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.Cancer Res.1979;39:3220\u20134.","journal-title":"Cancer Res."},{"key":"1036_CR41","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/ijc.25431","volume":"127","author":"LM Shelton","year":"2010","unstructured":"Shelton LM, Huysentruyt LC, Seyfried TN. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. International journal of cancer. J Int Cancer. 2010;127:2478\u201385.","journal-title":"J Int Cancer"},{"key":"1036_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1593\/neo.91272","volume":"12","author":"YC Tzuman","year":"2010","unstructured":"Tzuman YC, Sapoznik S, Granot D, Nevo N, Neeman M. Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins. Neoplasia. 2010;12:51\u201360.","journal-title":"Neoplasia."},{"key":"1036_CR43","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1038\/emboj.2010.254","volume":"29","author":"SY Park","year":"2010","unstructured":"Park SY, Kim HS, Kim NH, Ji S, Cha SY, Kang JG, et al. Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J. 2010;29:3787\u201396.","journal-title":"EMBO J"},{"key":"1036_CR44","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/ncb1470","volume":"8","author":"WH Yang","year":"2006","unstructured":"Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol. 2006;8:1074\u201383.","journal-title":"Nat Cell Biol"},{"key":"1036_CR45","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1074\/mcp.R113.029751","volume":"12","author":"H-B Ruan","year":"2013","unstructured":"Ruan H-B, Nie Y, Yang X. Regulation of protein degradation by O-GlcNAcylation: crosstalk with ubiquitination. Mol Cell Proteom. 2013;12:3489\u201397.","journal-title":"Mol Cell Proteom"},{"key":"1036_CR46","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1021\/ac040044g","volume":"76","author":"D Hirschberg","year":"2004","unstructured":"Hirschberg D, Jagerbrink T, Samskog J, Gustafsson M, Stahlberg M, Alvelius G, et al. Detection of phosphorylated peptides in proteomic analyses using microfluidic compact disk technology. Anal Chem. 2004;76:5864\u201371.","journal-title":"Anal Chem"},{"key":"1036_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/ajh.2009.39","volume":"22","author":"F Martinez","year":"2009","unstructured":"Martinez F, Mansego ML, Escudero JC, Redon J, Chaves FJ. Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am J Hypertens. 2009;22:649\u201355.","journal-title":"Am J Hypertens"},{"key":"1036_CR48","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/sj.npp.1301260","volume":"32","author":"M Kuningas","year":"2007","unstructured":"Kuningas M, de Rijk RH, Westendorp RG, Jolles J, Slagboom PE, van Heemst D. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. Neuropsychopharmacology. 2007;32:1295\u2013301.","journal-title":"Neuropsychopharmacology"},{"key":"1036_CR49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","volume":"11","author":"T Cai","year":"2020","unstructured":"Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, et al. Sodium\u2013glucose cotransporter 2 inhibition suppresses HIF-1\u03b1-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020;11:390.","journal-title":"Cell Death Dis"},{"key":"1036_CR50","doi-asserted-by":"publisher","first-page":"e129034","DOI":"10.1172\/jci.insight.129034","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight. 2020;5:e129034.","journal-title":"JCI Insight"},{"key":"1036_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000091456","volume":"17","author":"K Drumm","year":"2006","unstructured":"Drumm K, Kress TR, Gassner B, Krug AW, Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem. 2006;17:21\u201328.","journal-title":"Cell Physiol Biochem"},{"key":"1036_CR52","doi-asserted-by":"publisher","first-page":"F1185","DOI":"10.1152\/ajprenal.90217.2008","volume":"296","author":"PS Pergher","year":"2009","unstructured":"Pergher PS, Leite-Dellova D. Mello-Aires Md. Direct action of aldosterone on bicarbonate reabsorption in in vivo cortical proximal tubule. Am J Physiol-Ren Physiol. 2009;296:F1185\u2013F1193.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"1036_CR53","doi-asserted-by":"publisher","first-page":"F682","DOI":"10.1152\/ajprenal.00172.2010","volume":"300","author":"DCA Leite-Dellova","year":"2011","unstructured":"Leite-Dellova DCA, Malnic G, Mello-Aires M. Genomic and nongenomic stimulatory effect of aldosterone on H+-ATPase in proximal S3 segments. Am J Physiol-Ren Physiol. 2011;300:F682\u2013F691.","journal-title":"Am J Physiol-Ren Physiol"},{"key":"1036_CR54","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.bbamcr.2013.05.009","volume":"1833","author":"SA Salyer","year":"2013","unstructured":"Salyer SA, Parks J, Barati MT, Lederer ED, Clark BJ, Klein JD, et al. Aldosterone regulates Na+, K+ ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor. Biochimica et Biophysica Acta (BBA) - Mol Cell Res. 2013;1833:2143\u201352.","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Cell Res"},{"key":"1036_CR55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.lfs.2009.01.007","volume":"84","author":"P Degrell","year":"2009","unstructured":"Degrell P, Cseh J, Mohas M, Molnar GA, Pajor L, Chatham JC, et al. Evidence of O-linked N-acetylglucosamine in diabetic nephropathy. Life Sci. 2009;84:389\u201393.","journal-title":"Life Sci"},{"key":"1036_CR56","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1210\/en.2006-0944","volume":"147","author":"C Guo","year":"2006","unstructured":"Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363\u201373.","journal-title":"Endocrinology."},{"key":"1036_CR57","doi-asserted-by":"publisher","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","volume":"297","author":"SH Lee","year":"2009","unstructured":"Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Ren Physiol. 2009;297:F1381\u20131390.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1036_CR58","doi-asserted-by":"publisher","first-page":"15589","DOI":"10.1074\/jbc.M701762200","volume":"282","author":"SS Andrali","year":"2007","unstructured":"Andrali SS, Qian Q, Ozcan S. Glucose mediates the translocation of NeuroD1 by O-linked glycosylation. J Biol Chem. 2007;282:15589\u201396.","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1038\/s41440-023-01167-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000}}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01036-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01036-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01036-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T08:07:31Z","timestamp":1673597251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-01036-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-01036-6","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"13 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41440-023-01167-4","URL":"https:\/\/doi.org\/10.1038\/s41440-023-01167-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HS has an honorarium from Daiichi-Sankyo Company, Mochida Pharmaceuticals, Astrazeneca, Novartis Pharma, Bayer, and Astellas. HS also received scholarships from Chugai and Bayer. Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}